Please assess the completion status of the following clinical trial:

Trial Title: Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~1. Previously completed 24 weeks of therapy and 4 weeks of follow-up in the REPLACE study~2. With regard to female patients: women who are postmenopausal or willing to use two medically acceptable methods of contraception for the duration of the study with pregnancy testing conducted at every scheduled office visit~3. Total serum calcium ≤ ULN based on local laboratory results prior to randomization~4. Serum 25(OH) vitamin D ≤ 1.5 times the ULN within approximately 8 weeks prior to randomization~Main Exclusion Criteria:~1. Any disease or condition that, in the opinion of the investigator, has a high probability of precluding the patient from completing the study or being able to appropriately comply with study requirements~2. Use of raloxifene hydrochloride or intravenous (IV) bisphosphonates since the end of participation in the REPLACE trial~3. Chronic (ie, ≥ 1 month exposure) use of systemic corticosteroids, oral bisphosphonates, calcitonin, fluoride tablets, or cinacalcet hydrochloride~4. Pregnant or lactating women~5. Any condition that would, in the investigator's opinion in consultation with the sponsor, preclude the safe use of PTH~6. Use of any experimental drug other than NPSP558 within 3 months of baseline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 25 µg dose (Type: EXPERIMENTAL): 25 µg
- 50 µg dose (Type: EXPERIMENTAL): 50 µg

Based on this trial design, predict the completion outcome and termination type (if applicable).